Compare IOP Reduction

arrow Created with Sketch.
arrow Created with Sketch.
15 Products

reset all

At-a-Glance

Description

FDA

CE Mark

Active Ingredients

Application

Status

Strength

remove

close Created with Sketch.
  • Preservative-free glaucoma drops in a multidose bottle
  • Six (6) multi-agent combinations of two or more molecules
  • Compounded, multiagent formulations may benefit patients with convenience and cost-savings
  • Poloxamer 407 based vehicle
  • Potency testing performed to confirm consistent amount of each drug delivered

A line of preservative-free compounded glaucoma agents

No (compounded formulation)

No

Formulation dependent

Topical

Prescription

Formulation dependent

remove

close Created with Sketch.
  • Mechanism of Action: Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).
  • Dosage: One drop in the affected eye(s) three times a day

Azopt (brinzolamide ophthalmic suspension) 1% is an eye drop to lower intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension. It belongs to a class of drugs known as carbonic anhydrase inhibitors, and works by decreasing the amount of fluid within the eye.

Yes

Not specified

Brinzolamide

Topical

Prescription

1%

remove

close Created with Sketch.
  • Mechanism of Action: Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brinzolamide has a peak ocular hypotensive effect occurring at 2 to 3 hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Brimonidine tartrate has a peak ocular hypotensive effect occurring at two hours post-dosing. The result is a reduction in intraocular pressure (IOP).
  • Dosage: One drop in the affected eye(s) three times daily

Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Yes

Not specified

Brinzolamide/brimonidine tartrate

Topical

Prescription

1%/0.2%

remove

close Created with Sketch.
  • Mechanism of Action: Travoprost free acid is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing trabecular meshwork and uveoscleral outflow. The exact mechanism of action is unknown at this time.
  • Dosage: One drop in the affected eye(s) once-daily in the evening

Travatan Z (travoprost ophthalmic solution) 0.004% is a synthetic prostaglandin F2? analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.

Yes

Not specified

Travoprost

Topical

Prescription

0.004%

remove

close Created with Sketch.
  • Mechanism of Action: Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
  • Dosage: One drop in the affected eye(s) once daily in the evening

Lumigan (bimatoprost ophthalmic solution) 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Yes

Not specified

Bimatoprost

Topical

Prescription

0.01%

remove

close Created with Sketch.
  • Mechanism of Action: Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
  • Dosage: One drop in the affected eye(s) once daily in the evening

Lumigan (bimatoprost ophthalmic solution) 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Yes

Not specified

Bimatoprost

Topical

Prescription

0.03%

remove

close Created with Sketch.
  • Mechanism of Action: Alphagan P is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
  • Dosage: One drop in the affected eye(s) three times daily.

Alphagan P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% is a relatively selective alpha-2 adrenergic agonist indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Yes

Not specified

Brimonidine tartrate

Topical

Prescription

0.1%,0.15%

remove

close Created with Sketch.
  • Mechanism of Action: Combigan is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Timolol maleate is a beta1 and beta2 adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.
  • Dosage: One drop in the affected eye(s), twice daily approximately 12 hours apart.

Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Yes

Not specified

Brimonidine tartrate/timolol maleate

Topical

Prescription

0.2%/0.5%

remove

close Created with Sketch.
  • Mechanism of Action: Timolol maleate is a beta1 and beta2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.
  • Dosage: The starting dose is one drop in the affected eye(s) once daily in the AM. If the patient's intraocular pressure is not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.

Istalol (timolol maleate ophthalmic solution) 0.5% is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma

Yes

Not specified

Timolol maleate

Topical

Prescription

0.5%

remove

close Created with Sketch.
  • Mechanism of Action: Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.
  • Dosage: One drop in the affected eye(s) once daily in the evening.

Vyzulta (latanoprostene bound ophthalmic solution 0.024%), is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Vyzulta is the first prostaglandin analog with one of its metabolites being nitric oxide (NO).

Yes

Yes

Latanoprostene bunod

Topical

Prescription

0.024%

remove

close Created with Sketch.
  • Mechanism of Action: Tafluprost acid, a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
  • Dosage: One drop in the affected eye(s) once daily in the evening.

Zioptan (tafluprost ophthalmic solution) 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The preservative-free solution is packaged in individual single-use containers.

Yes

Not specified

Tafluprost

Topical

Prescription

0.0015%

remove

close Created with Sketch.
  • Mechanism of Action: Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).
  • Dosage: One drop in the affected eye(s) three times daily

Trusopt (dorzolamide hydrochloride ophthalmic solution) 2% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Yes

Not specified

Dorzolamide hydrochloride

Topical

Prescription

2%

remove

close Created with Sketch.
  • Mechanism of Action: Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow.
  • Dosage: One drop in the affected eye(s) once-daily in the evening

Xalatan (latanoprost ophthalmic solution) 0.005% is a prostaglandin F2? analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Yes

Not specified

Latanoprost

Topical

Prescription

0.005%

remove

close Created with Sketch.
  • Mechanism of Action: Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork route. The exact mechanism is unknown.
  • Dosage: The recommended dosage is one drop once daily in the evening.

Rhopressa (netarsudil ophthalmic solution) 0.02% is a rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rhopressa only requires one drop of medication per day, taken in the evening.

Yes

Not specified

Netarsudil

Topical

Prescription

0.02%

remove

close Created with Sketch.
  • Mechanism of Action: Netarsudil is a rho kinase inhibitor, which is believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork route. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow.
  • Dosage: This medication is still under investigation but the recommended dosage will likely be one drop once daily in the evening.

Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% is a fixed-dose combination of Rhopressa and latanoprost, a prostaglandin analog. The once-daily eyedrop is intended to reduce intraocular pressure in patients with glaucoma or ocular hypertension.

Under investigation

Not specified

Netarsudil/Latanoprost

Topical

Prescription

0.02%/0.005%